The five-year grant from NASA will go toward creating the NASA MIRO Inflatable Deployable Environments and Adaptive Space Systems Center at UH. Photo via UH.edu

The University of Houston was one of seven minority-serving institutions to receive a nearly $5 million grant this month to support aerospace research focused on extending human presence on the moon and Mars.

The $4,996,136 grant over five years is funded by the NASA Office of STEM Engagement Minority University Research and Education Project (MUREP) Institutional Research Opportunity (MIRO) program. It will go toward creating the NASA MIRO Inflatable Deployable Environments and Adaptive Space Systems (IDEAS2) Center at UH, according to a statement from the university.

“The vision of the IDEAS2 Center is to become a premier national innovation hub that propels NASA-centric, state-of-the-art research and promotes 21st-century aerospace education,” Karolos Grigoriadis, Moores Professor of Mechanical Engineering and director of aerospace engineering at UH, said in a statement.

Another goal of the grant is to develop the next generation of aerospace professionals.

Graduate, undergraduate and even middle and high school students will conduct research out of IDEAS2 and work closely with the Johnson Space Center, located in the Houston area.

The center will collaborate with Texas A&M University, Houston Community College, San Jacinto College and Stanford University.

Grigoriadis will lead the center. Dimitris Lagoudas, from Texas A&M University, and Olga Bannova, UH's research professor of Mechanical Engineering and director of the Space Architecture graduate program, will serve as associate directors.

"Our mission is to establish a sustainable nexus of excellence in aerospace engineering research and education supported by targeted multi-institutional collaborations, strategic partnerships and diverse educational initiatives,” Grigoriadis said.

Industrial partners include Boeing, Axiom Space, Bastion Technologies and Lockheed Martin, according to UH.

UH is part of 21 higher-education institutions to receive about $45 million through NASA MUREP grants.

According to NASA, the six other universities to received about $5 million MIRO grants over five years and their projects includes:

  • Alaska Pacific University in Anchorage: Alaska Pacific University Microplastics Research and Education Center
  • California State University in Fullerton: SpaceIgnite Center for Advanced Research-Education in Combustion
  • City University of New York, Hunter College in New York: NASA-Hunter College Center for Advanced Energy Storage for Space
  • Florida Agricultural and Mechanical University in Tallahassee: Integrative Space Additive Manufacturing: Opportunities for Workforce-Development in NASA Related Materials Research and Education
  • New Jersey Institute of Technology in Newark:AI Powered Solar Eruption Center of Excellence in Research and Education
  • University of Illinois in Chicago: Center for In-Space Manufacturing: Recycling and Regolith Processing

Fourteen other institutions will receive up to $750,000 each over the course of a three-year period. Those include:

  • University of Mississippi
  • University of Alabama in Huntsville
  • Louisiana State University in Baton Rouge
  • West Virginia University in Morgantown
  • University of Puerto Rico in San Juan
  • Desert Research Institute, Reno, Nevada
  • Oklahoma State University in Stillwater
  • Iowa State University in Ames
  • University of Alaska Fairbanks in Fairbanks
  • University of the Virgin Islands in Charlotte Amalie
  • University of Hawaii at Manoa in Honolulu
  • University of Idaho in Moscow
  • University of Arkansas in Little Rock
  • South Dakota School of Mines and Technology in Rapid City
  • Satellite Datastreams

NASA's MUREP hosted its annual "Space Tank" pitch event at Space Center Houston last month. Teams from across the country — including three Texas teams — pitched business plans based on NASA-originated technology. Click here to learn more about the seven finalists.

Houston-based Mainline is providing the tournament software for an unprecedented esports showdown between the Big 12 schools. Jamie McInall/Pexels

Houston esports company to provide software for a first-of-its-kind collegiate tournament

game on

While college football's fate this fall is up in the air thanks to the coronavirus pandemic, the Big 12 Conference is definitely going to face off virtually thanks to esports software developed in Houston.

According to an announcement from the Big 12 Conference and Learfield IMG College, its multimedia rights partner, the tournament has opened for registration for all 10 member schools — Baylor University, Texas Christian University, University of Texas, Texas Tech University, Iowa State University, University of Kansas, Kansas State University, University of Oklahoma, Oklahoma State University, and West Virginia University.

"This is a great opportunity to engage in an emerging space on a Conference-wide level," says Big 12 Commissioner Bob Bowlsby in a news release. "This opportunity is a unique way to provide original content from within a competitive environment during these challenging times. We appreciate the collaborative efforts that have made this first-of-its-kind Big 12 Championship tournament possible."

Houston-based Mainline, an esports software startup, has been selected to provide the tournament software for this unprecedented event, which is set to take place July 13 to 16. Each of the 10 schools will host its own single-elimination qualifying tournament featuring Madden NFL 20. Students have until July 10 to register to compete. Big 12 Now on ESPN+ will air both the schools' finals and the Big 12 Conference Championship tournament. The host of Big 12 This Week, Bill Pollock, will call the tournament.

Not only will Mainline's tournament software enable the competition, but it will allow Learfield IMG College to sell sponsors on esports visibility. Just like the football season, the esports tournaments will promote school branding and an opportunity to connect with student participants.

"It's more important now than ever to provide college students the ability to stay connected and engaged, and our technology can help aggregate the college esports community to help make that happen," says Chris Buckner, Mainline's CEO and founder, in the release. "This will multiply the opportunity, power and fun of esports to college students attending all Big 12 universities and keeps students competing while still practicing social distancing."

Earlier this month, Buckner joined InnovationMap's Houston Innovators Podcast to discuss the opportunities — as well as the challenges — the pandemic posed for his company.

"Everyone is looking for how to get sports, or esports, in front of people because everyone is just missing [sports] so much," Buckner says on the episode. "Our June will pretty much be the best month of our company, and a lot of that is driven by the fact that everyone is looking for a digital solution rather than an in-person solution."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”